Biochip for detection of inflammatory bowel disease

January 26, 2005

The project developing the biochip, known as the IBDChip, was carried out with the collaboration of Dr. Miquel Sans of the Gastroenterology Service at the Barcelona Hospital Clínico and Dr. Carlos Cara of UCB Pharma. The biochip is currently analysing 46 mutations related to inflammatory bowel disease (EII) and will shortly begin clinical trials.

The polymorphisms analysed are diverse and enable the establishment of the risk of suffering from the disease, its prognosis and the response of the patient to the pharmacological treatment.

From a clinical practice viewpoint the implantation of the IBDchip has a twin usefulness: it enables the selection of the most suitable therapy for each patient and it also determines, in those family members of EII sufferers who wish to be tested, the degree of predisposition for developing the infirmity.

Inflammatory bowel disease (EII) includes Crohn's Disease (CD) and Ulcerous Colitis (UC), disorders of particular importance in gastroenterology both amongst children and adults. The evidence for a genetic origin to the illness is a fact. Between 10 and 20 per cent of family members of CD and UC patients, also have these diseases. The IBDchip is an open tool which to date includes the polymorphisms associated in the literature with the disease, the predisposition to the disease nd its evolution. As new mutations are identified, these can be easily incorporated into the IBDchip for their analysis.

Progenika, a biotechnology company of the Basque Country, pioneer in this field in Spain, has already developed other, similar products. An example is the Lipochip developed for the Lácer pharmaceutical company and which diagnoses family hypercholesterolemia. The Lipochip was the first biochip to obtain European Commission certificate for its diagnostic use.

The Bloodchip, a biochip for genotyping blood donors, is another example. This biochip has recently started clinical trials in Spain, Germany, the UK, Holland and the Czech Republic using more than 4,000 donors.
-end-


Elhuyar Fundazioa

Related Inflammatory Bowel Disease Articles from Brightsurf:

People with inflammatory bowel disease still die earlier despite increase in life
A study comparing life expectancy of people with inflammatory bowel disease (IBD) and without found that, while life expectancy increased for both groups, people with IBD generally died sooner.

Cell therapy designed to treat inflammatory bowel disease
The UPV/EHU's NanoBioCel research group has for many years been developing systems enabling cells to be used as drugs.

Team develops wearable sensor to help people with inflammatory bowel disease
University of Texas at Dallas researchers have designed a wearable device that monitors sweat for biomarkers that could signal flare-ups of inflammatory bowel disease (IBD).

Antibiotics associated with increased risk of inflammatory bowel disease
Antibiotics use, particularly antibiotics with greater spectrum of microbial coverage, may be associated with an increased risk of new-onset inflammatory bowel disease (IBD) and its subtypes ulcerative colitis and Crohn's disease.

Yes, inflammatory bowel disease and celiac disease are linked
A systematic review and meta-analysis that has determined there is a nine-fold increased risk of having IBD for patients with a previous diagnosis of celiac disease.

The effects of inflammatory bowel disease on pregnancy
Inflammatory bowel disease (IBD) -- including Crohn's disease and ulcerative colitis -- often affects women of childbearing age.

5 major advances in inflammatory bowel disease (IBD) treatment
Summary of five impactful studies to be presented at the Crohn's & Colitis Congress, a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association (AGA).

Researchers identify a possible cause and treatment for inflammatory bowel disease
In a study published online in PNAS on Jan. 20, 2020, Prof.

Does inflammatory bowel disease carry certain risks during pregnancy?
Pregnant women with inflammatory bowel disease (IBD) are more likely to undergo delivery by Caesarean section and face certain risks during pregnancy, according to an analysis published in Alimentary Pharmacology & Therapeutics.

Inhibiting a protease could improve the treatment of inflammatory bowel disease
Scientists at the CNIC and CSIC have identified a function of a protease that could be the future target of drugs to treat inflammatory bowel disease.

Read More: Inflammatory Bowel Disease News and Inflammatory Bowel Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.